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ABSTRACT
Purpose: The aim of this retrospective study was to assess the safety and effectiveness of laser abla-
tion (LA) in patients with small renal cell carcinomas (RCC) and increased risk of bleeding.
Material and methods: From 2013 to 2017, nine patients (six males, three females, aged
68.5 ± 12.2 years) at high risk of bleeding underwent ultrasonography-guided LA for an RCC. Patients
were considered at increased risk of bleeding because of impairment of coagulation parameters, con-
comitant antiplatelet therapy, or at-risk location of the tumor (one, five, and three patients, respect-
ively). RCC diameter ranged from 11 to 23mm. According to tumor size, two or three laser fibers were
introduced through 21-gauge needles and 1800 J per fiber were delivered in 6min with a fixed power
of 5 W. Major and minor complications, technical success, and primary and secondary technical effect-
iveness and tumor recurrence were recorded.
Results: Just one Grade 1 complication was observed: a small asymptomatic hematoma that spontan-
eously resolved. Technical success was 100%, 1 month technical efficacy was 88.9% (8/9 patients). One
patient with residual tumor was successfully retreated 1 month later, and secondary efficacy rate
was 100%. No local tumor recurrence occurred during a median follow-up of 26 months
(range 11–49 months).
Conclusions: LA is safe and effective in the treatment of small RCC and might represent a valid option
in patients with increased risk of bleeding.
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Introduction
The detection rate of renal cell carcinoma (RCC) has
increased over the last few years, mainly due to the
increased number of incidentally diagnosed cases during
diagnostic cross-sectional studies. The majority of RCCs are
serendipitously found when of small dimensions, in T1a stage
[1,2]. Partial nephrectomy (open or laparoscopic) is the first
therapeutic option whenever it is technically feasible, as total
nephrectomy may often reduce renal function [3], and is
mainly reserved to centrally located tumors. Image-guided
ablation therapies are increasingly used as a valid option for
patients unsuitable for surgery in several different clinical
scenarios. In particular, they have been proposed as a safe
and effective alternative to surgery in small RCC, as these
therapies can result in up to 100% of tumor ablation and are
less invasive and more nephron-sparing [4,5]. Quite recently,
the Cardiovascular and Interventional Radiology Society of
Europe (CIRSE) published the guidelines for percutaneous
ablation of small RCC, recommending radiofrequency abla-
tion (RFA) and cryoablation (CRA) as the most studied and
most suitable modalities to ablate tumors up to 5 cm in
diameter, and mentioning also microwave ablation (MWA) as
an interesting and increasingly used technique, although at
present it is less investigated than RFA and CRA, and some
concerns exist concerning its higher risk of pelvicalyceal
injury [2].
Laser ablation (LA) uses laser optical fibers to deliver
energy to the tissue [6,7]. Although it is less investigated
than RFA and MWA, LA is currently used in many centers to
treat primary and metastatic liver cancers, with results that
are comparable to MWA and RFA [8–13]. The multifiber tech-
nique uses 300 lm bare optical fibers that are introduced
into the tumor through 21-gauge needles [14,15]. The nee-
dles are considerably thinner than RFA, MWA, and CRA devi-
ces, which may be advantageous in particular clinical settings
[15–17], mainly due to the very low invasiveness of the
device. In particular, LA might be the ideal ablative technique
in patients at high risk of complications due to the presence
of comorbidities or difficult technical access [14,18]. However,
to date, LA has not been thoroughly investigated in the
treatment of RCC, and the experiences in renal ablation
reported in literature are sporadic and almost anec-
dotal [1,19–21].
In our Department, we usually use RFA or MWA to ablate
RCC, but in patients with small renal tumors with increased
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procedural risk we prefer to use LA because of the smaller
diameter of the device and its minimal invasiveness.
Thus, the aim of the present article was to retrospectively
assess the safety and effectiveness of LA in patients with
small RCCs at high risk of bleeding.
Materials and methods
The records of patients who underwent ultrasonography
(US)-guided percutaneous ablation from August 2013 to
January 2017 were retrospectively reviewed, and patients
who were treated with LA due to increased risk of bleeding
were analyzed. Institutional review board approval was
obtained, and patients’ informed consent was waived.
Patients gave their written informed consent to the ablation
procedure after all were judged unsuitable for surgery by a
panel of experts that included the urologist, anesthesiologist,
oncologist, and interventional radiologist. Cause of exclusion
from surgery were comorbidity (five patients) or advanced
chronic renal failure (four patients). In four cases with incon-
clusive radiologic findings, RCC was diagnosed by US-guided
biopsy; in the other cases the diagnosis was based on the
imaging findings, and US-guided biopsy was performed
immediately before the ablation procedure. According to
prior recommendations [22,23], biopsy in these cases was
aimed at obtaining information on the histology and grade
of the tumor in order to plan surveillance after LA. Tumor
size ranged from 11 to 23mm in their largest diameter
(median 18mm). The patients underwent LA instead of other
ablative techniques because they were considered at
increased risk of bleeding: in three patients RCC was not exo-
phytic, and a sizeable portion of renal parenchyma had to be
passed through to reach the tumor (Figure 1(a)); one patient
had low platelet count (50,000 platelets/mcL) and INR of 1.56
because of concomitant liver cirrhosis; five patients could not
discontinue their antiplatelet therapy for ischemic heart dis-
ease with coronary stent implantation.
Ablation procedure
LA was performed on an inpatient basis by using a commer-
cially available system composed of a US device and a laser
unit (Echolaser; Elesta Srl, Florence, Italy). The laser source is
a semi-conductor diode with a wavelength of 1064 nm, and a
Figure 1. (a) CEUS scan showing a Bosniak III renal cyst cytologically proven to be RCC (arrow): 11.5mm of renal parenchyma had to be passed through to reach
the cyst (cross-shaped markers). (b) US scan showing the tip of a 21-G needle inside the BosnIak III cyst (arrow). (c) The steam produced by LA spreading inside the
Bosniak III cyst (arrow). (d) Post-procedural CEUS scan showing a non-enhancing zone completely covering the Bosniak III cyst.
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multi-source device (Figure 2) permits the use of up to four
300lm fibers at once, making it possible to obtain ablation
areas up to 4 cm in diameter [9,14,15].
LA procedures were performed by two physicians with
more than 10 years of experience in US-guided ablations of
liver and kidney tumors. If the tumor was adjacent to the
colon, preliminary hydrodissection by instilling 5% dextrose
solution was performed to obtain a 2 cm safety margin
between the colon and the tumor. After local anesthesia with
lignocaine 1% 10ml and conscious sedation with intravenous
midazolam and ramifentanil, laser fibers were introduced into
the tumor under US guidance through 21-gauge Chiba nee-
dles (Figure 1(b)). Two laser fibers spaced 12mm apart were
used for lesions with a diameter up to 14mm, and three
fibers with isosceles triangle configuration spaced 6–12mm
apart were inserted if the diameter of the lesions exceeded
14mm; the pullback technique [14,15] was used if the
antero-posterior diameter of the nodules exceeded 12mm.
The needles were introduced by using a guidance device
with separate channels at prefixed distance (from 2 to
18mm) (Elesta Srl, Florence, Italy) (Figure 3). The laser
machine was set at a power of 5 W, and 1800 J per fiber
were delivered in 6min, with the spread of the steam inside
the tumor monitored by real-time US (Figure 1(c)); a further
1800 J were delivered if the pullback technique was used.
The completeness of the ablation was assessed by contrast-
enhanced US (CEUS) performed about 10min after the end
of the procedure. An 8 lL/mL solution of sulfur hexafluoride
microbubbles stabilized by a phospholipid shell (SonoVueVR ;
Bracco, Milan, Italy) was used as contrast agent, and CEUS
was performed by using a low mechanical index contrast-
specific nonlinear technique (CnTI; Esaote, Genova, Italy). If
no enhancing zone with diameters equal to or greater than
those of the treated tumor was depicted, the treatment was
considered complete (Figure 1(d)). If residual enhancing foci
of tumoral tissue were identified, another one or two laser
fibers were inserted into the viable foci under CEUS guid-
ance, and a further 1800J per fiber were delivered to com-
plete the treatment.
Post-procedural care and follow-up
After LA, the patients remained in the hospital overnight and
their vital signs were monitored. The next morning, clinical
evaluation and US examination of the abdomen were per-
formed, and the patients were discharged in the afternoon if
they were considered to be well.
All patients were followed up until death, dropout, or the
time the data were censored (22 December 2017). The
patients underwent contrast-enhanced computed tomog-
raphy (CECT), or CEUS if they had impaired renal function,
1 month after LA, and were subsequently monitored with
alternating CECT and CEUS (or only CEUS in presence of
reduced renal function) every 3 months for the first 2 years,
then every 6 months.
Variables
The number of fibers used in each case, with pullback when
needed, the presence or absence of residual disease at
immediate CEUS and number of patients immediately
retreated, and the number of cases requiring hydrodissection
were recorded. The duration of energy application and the
duration of the entire procedure (time from the patient’s
admission into the interventional suite to patient’s discharge
to the recovery unit) were also recorded. Technical success,
technical efficacy, primary and secondary efficacy rates, and
local tumor progression were recorded and defined accord-
ing to the recommendations of the International Working
Group on the Image-guided Tumor Ablation [24]. In particu-
lar, technical success addressed whether the tumor was
Figure 2. Laser ablation machine with multi-source device. Four 300 lm bare
optical fibers are connected.
Figure 3. Convex US probe with lateral-mounted laser needle guide: two nee-
dles spaced 12mm apart are inserted.
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treated according to protocol and whether it was completely
covered by the ablation zone. Technical efficacy was defined
as a non-enhancing area with diameters equal to or greater
than those of the treated tumors, assessed by a contrast-
enhanced imaging technique (CECT or CEUS) performed 1
month after LA (Figure 4(d,e)). If residual viable foci were
detected, the patient underwent further CEUS-guided LA and
the result was assessed by CEUS or CECT performed 1 month
later. Secondary efficacy rate was defined as the percentage
of tumors successfully eradicated following the first ablation
session or the ablation session performed to treat residual
tumor foci detected 1 month after the initial LA. Local tumor
progression was defined as the detection, 1 month after the
initial or repeated LA, of viable tumor foci within or close to
the ablated zone after complete ablation had
been documented.
Complications were recorded and classified according to
the CIRSE classification system for complications report-
ing [25].
Clinical data were retrospectively retrieved from the hos-
pital digital archive and images reviewed from the hospital
picture archiving and communication system.
Results
Patients and tumor characteristics are reported in detail in
Table 1.
Two laser fibers, three laser fibers, and three laser fibers
with the pullback technique were used in four, two, and
three patients, respectively. Hydrodissection was performed
in two cases. Post-procedural CEUS documented residual
viable foci in two patients, both of whom underwent further
CEUS-guided LA during the same treatment session, and
technical success was 100% (Figure 4(a–d)); CECT performed
after 1 month confirmed the completeness of the ablation
(Figure 4(e)).
Just one Grade 1 complication was observed: a small,
asymptomatic hematoma (maximum thickness 4mm) that
spontaneously resolved and did not require any intervention.
All the patients were discharged from the hospital the day
after the procedure.
Five patients were followed-up by alternating CECT and
CEUS, while four patients underwent only CEUS because of
reduced renal function. At 1 month, technical efficacy was
88.9% (eight out of nine patients). One patient showed a
residual viable tumor focus at CEUS performed 1 month after
LA procedure and was successfully retreated. Therefore, sec-
ondary efficacy rate was 100%. No local tumor progression
was demonstrated during a median follow-up of 26 months
(range 11–49 months). One patient died 17 months after LA
owing to acute cholecystitis and pneumonia; CECT performed
2 months before the death had documented complete tumor
ablation and partial involution of the ablation zone. Three
patients dropped out at 13, 33, and 49 months after LA,
respectively; none of them had local tumor progression at
the time they dropped out. Five patients were alive and dis-
ease-free at the time the data were censored (22
December 2017).
On the whole, the duration of energy application ranged
from 6 to 18min, and the duration of the entire procedure
ranged from 60 to 95min (mean 72min). All these data are
detailed in Table 2.
Discussion
The CIRSE guidelines recommend percutaneous ablation as
an effective and safe alternative to partial nephrectomy in
patients with T1a RCC who are not fit or are not willing to
undergo surgical treatment [2]. To date, RFA and CRA are the
most extensively used and studied ablation techniques, with
complete ablation rates up to 100% in tumors <3 cm and
90% for sizes between 3 and 5 cm, with over 90% 5 year dis-
ease-free survival for T1a lesions [4,5,26–29]. MWA is also
increasingly used for the treatment of RCC. In comparison
with RFA, it can obtain larger ablation areas and is not lim-
ited by the heat sink effect, desiccation, or charring [30,31].
However, MWA produces ablation zones that are often ovoid
[32], and even with the use of the novel antennas that offer
more spherical ablation zones than did the earlier ones,
MWA seems to have higher risk of pelvicalyceal injury than
the other ablation techniques [33].
Even though LA has been less investigated than RFA and
MWA, it is currently used in many centers to treat hepatocel-
lular carcinoma (HCC) and liver metastases (LM), with very
good results that are comparable to those of RFA and MWA
for either HCC [8,34,35] or LM from colorectal cancer
[10,11,36]. Moreover, no significant differences between LA
and RFA in terms of local tumor control, overall survival, and
Table 1. Patients and tumor characteristics.
Patients
Characteristics 1 2 3 4 5 6 7 8 9
Gender Male Female Male Female Male Male Male Male Female
Age, years 58 77 51 80 52 82 68 80 69
Tumor size, mm
(largest diameter)
18 22 12 11 18 15 20 20 23
Kidney side Left Right Right Left Left Left Left Left Right
Tumor type Exophytic Central Exophytic Exophytic Exophytic Exophytic Exophytic Exophytic Parenchymal
Histology U. caa Clear cell Clear cell Papillary U. caa Clear cell Clear cell Clear cell Clear cell
Fuhrman grade n.a. 1 1 1 n.a. 1 2 n.a 1
Reason for LA Antiplatelet
therapy
SRPPb INR 1.56
PLTs 50,000
Antiplatelet
therapy
SRPPb Antiplatelet
therapy
Antiplatelet
therapy
Antiplatelet
therapy
SRPPb
LA: laser ablation; n.a.: not available; INR: International Normalized Ratio; PLTs: platelets.
aUndetermined carcinoma.
bSizeable portion of renal parenchyma to be passed through.
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safety were found in two randomized trials that compared
the two techniques [13,35]. According to the multifiber tech-
nique [14,15], 300 lm bare optical fibers are introduced into
the tumor through 21-gauge needles, and the possibility of
using very thin needles makes LA particularly suitable for
ablating lesions in an at-risk location or in locations that are
difficult to reach [9,16–18].
However, at present, LA is not currently used to treat RCC,
and the studies reported in literature have been sporadic
and have involved very small series of patients [1,19–21].
Moreover, in all these studies, LA was performed under
Figure 4. (a) CT scan showing an exophytic hyperenhancing nodule in the middle third of the left kidney (arrow). (b) US scan showing the same nodule (arrow).
(c) Post-procedural CEUS scan showing residual enhancing tissue (arrowhead) in the inferolateral margin of the ablation zone (arrow). The residual viable tissue is
targeted for immediate retreatment under CEUS guidance (dotted lines). (d) CEUS scan performed after the retreatment showing disappearance of the residual
enhancing tissue (arrow). (e) CECT scan performed 1 month after LA showing complete disappearance of enhancement of the nodule with fibrosis of the
surrounding fat (arrow).
Table 2. LA procedure characteristics.
Patients
Characteristics 1 2 3 4 5 6 7 8 9
Hydrodissection No Yes No Yes No No No No No
Number of fibers 3 3 2 2 3 2 2 3 3
Pullback Yes Yes No No No No No No Yes
Additional LAa No Yes No No Yes No No No No
Duration of energy
deposition (min)
12 18 6 6 12 6 6 6 12
Duration of procedure (min) 70 95 60 65 90 60 70 65 75
Length of follow-up (months) 40 17 29 33 49 13 11 6 21
aAdditional laser ablation (LA) due to residual enhancing foci or small ablation
zone depicted by immediate post-procedural CEUS.
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magnetic resonance (MR) guidance by using large diameter
devices requiring the introduction of a 9 French sheath into
the tumor. Instead, in our series, LA was performed under
US-guidance by using very thin needles. The kidney is a
hypervascular organ and is considered more at risk of bleed-
ing than the liver when interventional procedures are per-
formed [37,38], and needle size has been reported to be a
risk factor of hemorrhagic complications [39,40]. Therefore,
the use of thinner needles could provide some advantage
when thermal ablation is performed to treat RCC, in particu-
lar if the risk of bleeding is increased. Indeed, LA was pre-
ferred in our patients as they were considered at increased
risk of bleeding because of impairment of coagulation
parameters, concomitant antiplatelet therapy, or at-risk loca-
tion of the tumor. No major complication was observed, and
all tumors were completely ablated in one session (eight
cases) or two sessions (one case) of treatment. Moreover, no
local tumor progression occurred during the follow-up
period. Unlike in our series, in the few previous reports on
LA of RCCs the procedure was performed under MR guidance
[1,19,20]. The main advantage of MR over other imaging
modalities is its sensitivity to thermal changes [10,41], which
make it possible to monitor the heating process in near real
time to ensure that the entire lesion has been treated and to
reposition the applicators in case of residual tumor. However,
post-procedural CEUS in early evaluation of the ablation pro-
cedures has been proven to be as accurate as both CEUS
and CT performed at 24 h [42,43], and at present CEUS is rec-
ommended as a valid tool in the post-procedural assessment
of the completeness of ablation [44]. Indeed, post-procedural
CEUS documented an unsatisfactory ablation area in two out
of our nine patients (22.2%), both of whom were successfully
retreated under CEUS guidance in the same treatment ses-
sion, with a 100% technical success. Therefore, we think that
post-procedural CEUS can counterbalance the advantage of
MR in terms of correct evaluation of the completeness of the
treatment, allowing for US-guided ablation whenever the
tumor can be well-visualized and confidently targeted by US,
with obvious cost savings and shorter duration of the pro-
cedure. Indeed, in our series the mean duration of the entire
procedure was 72min versus a reported duration of 3.5 h
using MR-guided LA [1].
Our study has some limits. In particular, it is retrospective,
and the number of patients treated with LA is quite low. It
follows that our results can only be regarded as preliminary.
Moreover, the follow-up was relatively short in comparison
with the trials that investigated RFA and CRA of RCC.
However, a study on a 14 year experience of RFA in the
treatment of renal cancer has recently demonstrated that the
majority of recurrences are detected within the first
24 months after the procedure, with a significant number
being diagnosed within the first 3 months after the ablation
sessions [45]. Therefore, it is likely that our median 26 month
follow-up is long enough to infer good long-term efficacy
of LA.
In conclusion, our retrospective study suggests that US-
guided percutaneous LA of small RCC is safe and effective
in the treatment of small RCC, and that it might also be
successfully used in cases at high risk of bleeding.
Our preliminary results justify the planning of larger
prospective trials aimed at investigating whether LA could
represent a valid alternative to RFA, CRA, or MWA in the
treatment of Stage T1a RCC, in particular in patients at
increased risk of bleeding.
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